A Pharmacokinetic Study of Larotinib in Subjects With Mild/Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

Z650-HI-105

To evaluate the pharmacokinetics and safety of Larotinib in subjects with mild and moderate hepatic function impairment and healthy subjects in a single-center, non-randomized, open, single-dose administration

2023-12-30

2024-12-30

2024-12-30

Not yet recruiting

Early phase I

32

Inclusion Criteria: * healthy subjects with normal hepatic function (cohorts A and C) : * 1. Sign the informed consent form before the trial； * 2. subjects and must be 18 to 70 years of age inclusive, Male or female. body weight \>50 kg (male) or ≥45 kg (female) at screening. (BMI) : 18-30 kg/m\^2, (including critical value) \[BMI= weight (kg)/height\^2 (m\^2)\] (BMI matching ±15% with liver dysfunction cohort); * 3.Must be in good health as determined by past medical history, physical examination, vital signs, ECG, and laboratory tests at Screening； * 4.Subjects (including partners) have no pregnancy plan within 6 months after the last dose of study drug and voluntarily take effective contraceptive measures. * Subjects with mild/ Moderate hepatic Impairment (cohorts B and D) : * 1. Sign the informed consent form before the trial. * 2. subjects and must be 18 to 70 years of age inclusive, Male or female. body weight \>50 kg (male) or ≥45 kg (female) at screening. (BMI) : 18-30 kg/m\^2； * 3. Must satisfy the criteria for hepatic Impairment as evidenced by a Child-Pugh class of A or B at Screening:Class A; Mild; Child-Pugh score 5-6；Class B; Moderate; Child-Pugh score 7-9 * 4. The liver function status of the subjects was determined to be stable between 1 month before taking the experimental drug and the end of the study, with no significant change. * 5. Subjects (including partners) have no pregnancy plan within 6 months after the last dose of study drug and voluntarily take effective contraceptive measures. Exclusion Criteria: * ALL subjects * 1. The subject has been diagnosed with acquired immune deficiency syndrome (AIDS), or tests positive for human immunodeficiency virus (HIV). * 2. Currently suffering from any bleeding disease, such as gastric and duodenal ulcer * 3. Those who had undergone major surgery within 6 months before the screening period or the surgical incision did not completely heal; * 4. History of hand foot syndrome; * 5. Those who have a history of liver cancer or other malignant tumors before signing the informed consent * 6. Those who have a history of gastrointestinal and renal diseases or surgery that may affect drug absorption, distribution, metabolism and excretion within 6 months before screening, or have diseases that can reduce compliance * 7. Take any food or beverage products containing alcohol, caffeine, xanthine and grapefruit within 48 hours prior to the first dose. * 8. The subject has received blood within 1 month, or donated loss of blood over 400 mL within 3 months prior to the screening * 9. Have a history of alcoholism or positive alcohol breath test during the screening period; * 10. Those who smoke more than 5 cigarettes a day or habitually use nicotine containing products 3 months before screening * 11. Those who had a history of drug abuse or used drugs within 2 years before screening or those who were positive for urinary drug screening during the screening period Allergic constitution * 12. Allergic constitution * 13. Within 28 days before screening, inhibitors or inducers of CYP3A4, cyp2c8, CYP2C19 and P-gp were used * 14. Participated in any other intervention clinical trial within 3 months before screening * 15. Female subjects with positive pregnancy test results or breastfeeding during screening; * 16. Any other circumstances that the investigator considers unsuitable for participation in this study * The following exclusion criteria apply only to healthy subjects with normal hepatic function (cohorts A and C) : * 17. he subject has evidence of clinically significant cardiovascular, GI, renal, respiratory, endocrine, hematological, neurological, or psychiatric disease or abnormalities. * 18. The subject tests positive for HBsAg or Hepatitis C antibody * 19. The subject has used any prescription or nonprescription drugs within 2 weeks prior to the screening. * The following exclusion criteria apply only to subjects with mild/ Moderate hepatic Impairment (cohorts B and D) : * 17. The following exclusion criteria apply only to subjects with liver function impairment (cohorts B and D) : * a) ALT\>10×ULN； * b) AST\> 10×ULN； * c) Absolute count of neutrophils \<0.75×10\^9/L; * d) PLT\<50×10\^9/L * e) HGB\<60 g/L * f) AFP \>100 ng/mL; If 20 ng/mL≤AFP≤100 ng/mL, liver MRI are required to exclude subjects with suspected HCC. * g) eGFR\<60 mL/min/1.73m\^2. * h) Male：QTcF\> 450 msec，Female：QTcF\>470 msec。 * 18. The subject has any of the following conditions: Diseases affecting bile excretion such as biliary obstruction; Drug induced liver injury; History of liver transplantation; Liver failure, or liver cirrhosis patients with complications such as hepatic encephalopathy, rupture and bleeding of esophageal and gastric varices, etc; Patients with severe or advanced peritoneal effusion or pleural effusion need puncture drainage and albumin supplementation. Patients with hepatorenal syndrome. * 19. Previous severe esophagogastric varices or previous portosystemic shunt, including transjugular intrahepatic portosystemic shunt (TIPS) * 20. Cardiovascular events occurred within 6 months before screening * 21. Those who use prescription drugs, over-the-counter drugs, Chinese herbal medicine or food supplements other than drugs for the treatment of liver function impairment and other accompanying diseases within 14 days before screening; * 22. Medical conditions which are not adequately and stably controlled on stable doses of medications or which, in the clinical opinion of the Principal Investigator, may interfere with study procedures or participant safety.

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'This study is divided into four cohorts: healthy subjects in cohort A and C, mild liver function impairment subjects in cohort B, and moderateliver function impairment subjects in cohort D. Cohorts A and B, C and D should be matched in terms of gender, age, and body mass index (BMI).', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 32, 'type': 'ESTIMATED'}}

2023-03-21